...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cellular Physiology >Nanocurcumin restores aberrant miRNA expression profile in multiple sclerosis, randomized, double‐blind, placebo‐controlled trial
【24h】

Nanocurcumin restores aberrant miRNA expression profile in multiple sclerosis, randomized, double‐blind, placebo‐controlled trial

机译：Nanocurcumin恢复异常的microrna的表达在多发性硬化症,随机,双盲,应承担的安慰剂对照试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In the current study, we aimed to identify nanocurcumin effects on microRNAs (miRNAs) in the peripheral blood of patients with relapsing‐remitting multiple sclerosis (RRMS). We intended to investigate the expression pattern of these miRNAs in experimental settings in vivo. The expression levels of the selected 27 miRNAs known to be involved in the regulation of immune responses were analyzed in 50 RRMS patients and 35 healthy controls. The miRNA expression profiles were investigated by quantitative PCR (qPCR) at baseline and after 6 months of nanocurcumin therapy. Our data revealed that the expression of a number of microRNAs including miR‐16, miR‐17‐92, miR‐27, miR‐29b, miR‐126, miR‐128, miR‐132, miR‐155, miR‐326, miR‐550, miR‐15a, miR‐19b, miR‐106b, miR‐320a, miR‐363, miR‐31, miR‐150 , and miR‐340 is regulated by nanocurcumin. The results of the current work indicate that nanocurcumin is able to restore the expression pattern of dysregulated miRNAs in MS patients. We discovered that some miRNAs are deregulated in untreated patients compared with healthy controls and nanocurcumin‐treated patients. This is a new finding that might represent the potential contribution of these miRNAs to MS pathogenesis. Taken together, these data provide novel insights into miRNA‐dependent regulation of the function of B and T cells in MS disease and enrich our understanding of the effects mediated by a therapeutic approach that targets B and T cells.
机译：在目前的研究中,我们旨在识别nanocurcumin对小分子核糖核酸(microrna)的影响患者的外周血复发还是汇款多发性硬化症(名RRMS)。旨在调查的表达模式这些microrna在体内实验设置。所选的27种microrna的表达水平参与免疫的规定在50名RRMS患者和响应进行了分析35健康对照组。配置文件进行了定量PCR(qPCR)基线后6个月nanocurcumin疗法。许多小分子核糖核酸包括的表达式‐4‐我17‐92‐我27岁,我‐29b‐我126,米尔‐128、米尔‐132、miR‐155米尔‐326,米尔‐550‐我15a号,我‐19b‐我106b‐我320a‐我363,米尔米尔还是31日高150,米尔340是受nanocurcumin。表明nanocurcumin能够恢复microrna特异表达的表达模式病人。管制相比,未经治疗的患者健康对照组和nanocurcumin治疗病人。代表的潜在贡献microrna女士发病机理。数据提供新颖的见解microrna的依赖调节B细胞和T细胞的功能疾病和丰富我们的理解由一种治疗方法,效果目标B和T细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号